M. Sánchez Ronco

400 total citations
10 papers, 330 citations indexed

About

M. Sánchez Ronco is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Molecular Biology. According to data from OpenAlex, M. Sánchez Ronco has authored 10 papers receiving a total of 330 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 6 papers in Cancer Research and 4 papers in Molecular Biology. Recurrent topics in M. Sánchez Ronco's work include Cancer Genomics and Diagnostics (5 papers), Lung Cancer Treatments and Mutations (4 papers) and Lung Cancer Diagnosis and Treatment (3 papers). M. Sánchez Ronco is often cited by papers focused on Cancer Genomics and Diagnostics (5 papers), Lung Cancer Treatments and Mutations (4 papers) and Lung Cancer Diagnosis and Treatment (3 papers). M. Sánchez Ronco collaborates with scholars based in Spain and Greece. M. Sánchez Ronco's co-authors include Miquel Tarón, Enriqueta Felip, Joaquim Majó Fernández, Pedro Méndez, José Miguel Sánchez, Cristina Queralt, José Javier Sánchez, J Maestre, Rafael Rosell and John Souglakos and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Human Molecular Genetics.

In The Last Decade

M. Sánchez Ronco

10 papers receiving 324 citations

Peers

Countries citing papers authored by M. Sánchez Ronco

Since Specialization

Citations

This map shows the geographic impact of M. Sánchez Ronco's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Sánchez Ronco with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Sánchez Ronco more than expected).

Fields of papers citing papers by M. Sánchez Ronco

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Sánchez Ronco. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Sánchez Ronco. The network helps show where M. Sánchez Ronco may publish in the future.

Co-authorship network of co-authors of M. Sánchez Ronco

This figure shows the co-authorship network connecting the top 25 collaborators of M. Sánchez Ronco. A scholar is included among the top collaborators of M. Sánchez Ronco based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Sánchez Ronco. M. Sánchez Ronco is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

#	Work	Indexed citations
1	Multinodular and vacuolating brain tumors; what the radiologist needs to know 2020 ·(unknown), (unknown), M. Sánchez Ronco, Roger Lacave, I. Sánchez Lite, (unknown), (unknown), (unknown), (unknown)	1
2	3BA A phase II trial of erlotinib (E) and bevacizumab (B) in patients with advanced non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without T790M mutation. The Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) BELIEF trial 2015 ·European Journal of Cancer ·R. Stahel, Urania Dafni, Oliver Gautschi, Enriqueta Felip, Alessandra Curioni‐Fontecedro, Solange Peters, Bartomeu Massutí, F. Cardenal, (unknown), Martin Früh, Miklos Pless, Sanjay Popat, Α. Kotsakis, Sinéad Cuffe, Paolo Bidoli, Adolfo Favaretto, Enric Carcereny, M. Sánchez Ronco, (unknown), R. Rosell	24
3	ANGIOMET: Analysis of the correlations between angiogenic markers and outcome in patients (p) with advanced nonsquamous NSCLC (NS-NSCLC) treated with carboplatin, paclitaxel, and bevacizumab (CPB). 2014 ·Journal of Clinical Oncology ·Bartomeu Massutí, Eloísa Jantus‐Lewintre, (unknown), Delvys Rodríguez‐Abreu, Óscar Juan, Manuel Dómine, Mariano Provencio, J. Garde, Ramón García Gómez, I. Maestu, (unknown), Á. Artal, Christian Rolfo, Josefa Terrasa, Juana Oramás, R. de las Peñas, M. Sánchez Ronco, Javier de Castro, Rafael Rosell, Carlos Camps, (unknown)	1
4	Open, phase II randomized trial of gefitinib alone versus olaparib (AZD2281) plus gefitinib in advanced non-small cell lung cancer (NSCLC) patients (P) with epidermal growth factor receptor (EGFR) mutations: Spanish Lung Cancer Group trial (NCT=1513174/GECP-GOAL). 2014 ·Journal of Clinical Oncology ·Bartomeu Massutí, Rosario García Campelo, Delvys Rodríguez‐Abreu, Jordi Remón, Margarita Majem, (unknown), José Antonio Ortega, Francisco Aparisi, Noemı́ Reguart, María Ángeles Sala, Dolores Isla, M. Sánchez Ronco, (unknown), Miguel Ángel Molina‐Vila, (unknown), Eva Pereira, (unknown), (unknown), Enric Carcereny, Rafael Rosell, (unknown)	5
5	The Prognostic Value of BRCA1 mRNA Expression Levels Following Neoadjuvant Chemotherapy in Breast Cancer 2010 ·PLoS ONE ·Mireia Margelí Vila, Beatriz Cirauqui, Eva Castellà, Gustavo Tapia, Carlota Costa, Ana Giménez‐Capitán, Agustí Barnadas, M. Sánchez Ronco, Susana Benlloch, Miquel Tarón, Rafael Rosell	33
6	Mitotic checkpoint gene CHFR methylation in pretreatment serum DNA of docetaxel (doc)/cisplatin (cis)-treated stage IV non-small cell lung cancer (NSCLC) patients (p) 2006 ·Journal of Clinical Oncology ·Dolores Isla, (unknown), José Luis Ramírez, M. Sánchez Ronco, Manuel Cobo, Ana Fernández Montés, José Miguel Sánchez, (unknown), Miquel Tarón, Rafael Rosell	2
7	Efficacy and pharmacogenomic correlation of the combination of oxaliplatin and paclitaxel in first line advanced non-small cell lung cancer (NSCLC). Preliminary results of the Spanish Lung Cancer Group (SLCG) 0103 phase II trial 2006 ·Journal of Clinical Oncology ·Pilar Garrido, (unknown), (unknown), M. López-Brea, P. Lianes, J.L. González-Larriba, (unknown), M. Sánchez Ronco, Miquel Tarón, Rafael Rosell	2
8	Clinical Significance of Hypoxia-Inducible Factor–1α Messenger RNA Expression in Locally Advanced Non–Small-Cell Lung Cancer After Platinum Agent and Gemcitabine Chemotherapy Followed by Surgery 2005 ·Clinical Lung Cancer ·Enriqueta Felip, Miquel Tarón, Rafael Rosell, Pedro Méndez, Cristina Queralt, M. Sánchez Ronco, José Javier Sánchez, José Miguel Sánchez, J Maestre, Joaquim Majó Fernández	5
9	O-033 Docetaxel (DOC), cisplatin (CIS) and gemcitabine (GEM) asneoadjuvant treatment in stage IIIAN2 and T4N0-1 non-small cell lung cancer (NSCLC) patients (P). final results of SLCG phase II trial 9901 2005 ·Lung Cancer ·Pilar Garrido, Rafael Rosell, A. Antón Torres, J.L. González-Larriba, Mariano Provencio, Dolores Isla, (unknown), (unknown), M. Sánchez Ronco, Miquel Tarón	1
10	BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer 2004 ·Human Molecular Genetics ·Miquel Tarón, Rafael Rosell, Enriqueta Felip, Pedro Méndez, John Souglakos, M. Sánchez Ronco, Cristina Queralt, Joaquim Majó Fernández, José Miguel Sánchez, José Javier Sánchez, J Maestre	256

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact